Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology
Main finding · TIR 70 to 180 mg/dLResult — go to the resultMedian improvement 18.8% 95% CI 13.6–23.9Authors' conclusion
Computerized initiation and adaptation of Control-IQ technology settings from baseline MDI therapy was safe in adults with T1D. The use of this simplified system for onboarding and optimizing Control-IQ technology may be useful to increase uptake of AID and reduce staff and patient burden in clinical care.
Study context
- Population
- Adults with T1D using multiple daily injections (MDI); mean age 36.1 years, 57.6% female, diabetes duration 19.7 years
- Participants
- 33 adults
- Comparison
- Control-IQ with computerized settings initialization and adaptation vs MDI run-in
- Control-IQn = 33
- Run-inn = 33reference
- Outcome
- TIR 70 to 180 mg/dL
- Follow-up
- Last 30 days of Control-IQ use
Methodological details2-week continuous glucose monitoring (CGM) run-in, 13 weeks of Control-IQ use
- 2-week CGM run-in
- 13 weeks of Control-IQ use
Main finding
As reported in the abstract
Median improvement
18.8%
95% CI 13.6–23.9
P < 0.001
By group
Further findings
Time <70 mg/dL · over 13 weeks
- Time <70 mg/dL showed a gradual decreasing trend over time
Participants achieving HbA1c <7% · baseline to study end
- Participants achieving HbA1c <7%, baseline → study end
- 0 → 55%, P < .001
Automated settings adaptations overridden by investigators
- Automated settings adaptations overridden
- 6 of 318 (1.9%)
Safety
Automated settings adaptations overridden by investigators
- Overridden adaptations
- 6 of 318 (1.9%)
Original publication
Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology. J Diabetes Sci Technol. Published 7 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →